Hansa Biopharma AB
STO:HNSA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Hansa Biopharma AB
STO:HNSA
|
SE |
|
Northwest Pipe Co
NASDAQ:NWPX
|
US |
|
Medincell SA
PAR:MEDCL
|
FR |
|
G
|
Global Helium Corp.
CNSX:HECO
|
CA |
|
M
|
Mito Securities Co Ltd
TSE:8622
|
JP |
|
T
|
Tinybuild Inc
LSE:TBLD
|
US |
|
APQ Global Ltd
LSE:APQ
|
GG |
Hansa Biopharma AB
Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treats rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. The company is headquartered in Lund, Skane and currently employs 141 full-time employees. The company went IPO on 2007-10-17. The Company’s operations consist of research and development for drug discovery. The firm conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treats rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. The company is headquartered in Lund, Skane and currently employs 141 full-time employees. The company went IPO on 2007-10-17. The Company’s operations consist of research and development for drug discovery. The firm conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
